Printer Friendly

ISOMEDIX REPORTS RECORD SALES FOR THE FIRST QUARTER

 WHIPPANY, N.J., April 28 /PRNewswire/ -- Isomedix Inc. (NASDAQ: ISMX) today announced record sales for the first quarter ended March 31, 1993. For the three months ending March 31, Isomedix reported a 13 percent increase in consolidated sales to $9,572,657 compared with sales of $8,477,912 for the same period in 1992. Operating income increased 8 percent to $2,648,532 compared with $2,442,230 for the same period in 1992.
 Consolidated net income in the first quarter increased 10 percent to $1,669,844 compared with $1,519,704 earned a year ago. Based on 7,368,591 weighted average number of common shares outstanding in the first quarter compared with 7,132,359 shares a year ago, earnings per share were 23 cents for the first quarter compared with 21 cents for the same period in 1992, up 10 percent.
 "We are pleased to report increased sales in both gamma and ethylene oxide sterilization services for the quarter," said John Masefield, chairman and CEO of Isomedix. The gamma sector continued its strong growth and ethylene oxide sales increased, in part as a result of the commissioning of the chambers in Northborough, Mass.
 The construction of our Chester, New York gamma facility was completed in the 1st quarter of 1993, enabling the commencement of commercial late in the first quarter.
 Isomedix Inc., based in Whippany, N.J., operates a network of ten sterilization facilities in eight states and Canada. The capability to sterilize medical devices with pure ethylene oxide has now been added at three of the gamma facility locations. Isomedix also provides validation services through its Skyland Scientific Services subsidiary located in Montana.
 ISOMEDIX, INC.
 Condensed Consolidated Statements of Income
 (Unaudited)
 Periods ended March 31 Three Months
 1993 1992
 Sales $9,572,657 $8,477,912
 Operating income 2,648,532 2,442,230
 Net income 1,669,844 1,519,704
 Earnings per share $ .23 $ .21
 Weighted average number of shares
 outstanding 7,368,591 7,132,359
 -0- 4/28/93
 /CONTACT: Thomas J. DeAngelo, vice president-finance and administration of Isomedix, Inc., 201-887-4700/
 (ISMX)


CO: Isomedix Inc. ST: New Jersey IN: MTC SU: ERN

TM -- NY007 -- 1778 04/28/93 08:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1993
Words:371
Previous Article:MARVEL ENTERTAINMENT GROUP BOARD TO REMAIN NEUTRAL ON TENDER OFFER
Next Article:UNION CARBIDE REPORTS FIRST QUARTER RESULTS
Topics:


Related Articles
ISOMEDIX REPORTS RECORD SALES AND OPERATING INCOME FOR THE FIRST QUARTER
ISOMEDIX REPORTS RECORD SECOND QUARTER RESULTS
ISOMEDIX REPORTS RECORD FOURTH QUARTER AND RECORD YEAR END RESULTS; NET INCOME INCREASES 55 PERCENT
ISOMEDIX, INC. REVISES EARNINGS EXPECTATIONS
ISOMEDIX REPORTS RECORD SALES FOR THE THIRD QUARTER
ISOMEDIX REPORTS RECORD SALES FOR THE FOURTH QUARTER
ISOMEDIX REPORTS FIRST QUARTER RESULTS
ISOMEDIX REPORTS FIRST QUARTER RESULTS
ISOMEDIX REPORTS FIRST QUARTER RESULTS
Isomedix Reports Record Sales and Earnings

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters